Compare AstraZeneca plc (AZN) vs iShares 0 3 Month Treasury Bond ETF (SGOV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs iShares 0 3 Month Treasury Bond ETF — how do they compare? AstraZeneca plc trades at $157.51 (market cap $245.16B), while iShares 0 3 Month Treasury Bond ETF trades at $100.53. The key difference: AstraZeneca plc pays a 2.02% dividend while iShares 0 3 Month Treasury Bond ETF pays none, and iShares 0 3 Month Treasury Bond ETF is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.
| AZN | SGOV | |
|---|---|---|
Market Cap | $245.16B | — |
Sector | Health | Fixed Income |
52-Week High | $209.48 | $100.74 |
52-Week Low | $147.06 | $100.28 |
Enterprise Value | $272.43B | — |
Dividend Yield | 2.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
SGOV, the iShares 0-3 Month Treasury Bond ETF, trades at $100.52, up 0.02% with a bearish technical signal from moving averages. It offers a defensive cash alternative, highlighted by recent institutional stake changes and a focus on ultra-short Treasury exposure amid market volatility. The ETF provides monthly distributions, with recent dividends around $0.30 per share.
The outlook remains stable as a low-risk income vehicle, benefiting from rising yields and investor defensive pivots. Key risks include interest rate fluctuations and macroeconomic shifts, but its principal protection and liquidity appeal to cautious investors seeking yield above traditional savings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About iShares 0 3 Month Treasury Bond ETF
SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →
